Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition (Q24616631)
scientific article published on May 27, 2011
Language:
(P31) (Q13442814)
(P304) 5299-310
(P407) (Q1860)
(P433) 16
(P478) 17
(P577) Monday, August 15, 2011
Friday, May 27, 2011
(P953) https://aacrjournals.org/clincancerres/article-pdf/17/16/5299/1997336/5299.pdf
https://europepmc.org/articles/PMC3156934
https://europepmc.org/articles/PMC3156934?pdf=render
https://doi.org/10.1158/1078-0432.ccr-10-2847
https://aacrjournals.org/clincancerres/article-pdf/17/16/5299/1997336/5299.pdf
(P1433) (Q332253)
(P1476) "Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition" (language: en)
"Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition" (language: en)
(P2093) Elizabeth Allen
Douglas Hanahan
Ian B. Walters
(P2860) (Q24608039)
(Q24608005)
(Q27861075)
(Q28235646)
(Q29614537)
(Q29614302)
(Q29615445)
(Q35966757)
(Q37753858)
(Q33990834)
(Q35584074)
(Q37736273)
(Q37725350)
(Q34133084)
(Q37710828)
(Q37686529)
(Q39747642)
(Q37671366)
(Q39760940)
(Q33518926)
(Q33627739)
(Q37616590)
(Q37403323)
(Q36933339)
(Q37381550)
(Q37307140)
(Q34842280)
(Q34752683)
(Q34653494)
(Q30490422)
(Q36610990)
(Q36111400)
(Q35791487)
(Q31983397)
(Q32000651)
(Q41648802)
(Q46035627)
(Q51762694)
(Q46332916)
(Q46348954)
(Q45345159)
(Q44043154)
(Q44043137)
(Q56787224)
(Q43470250)
(Q84617438)
(Q84130682)
(Q37748050)
other details
description scientific article published on May 27, 2011

External Links